[CLLS] Cellectis S.A.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 17.25 Change: 0.2 (1.17%)
Ext. hours: Change: 0 (0%)

chart CLLS

Refresh chart

Strongest Trends Summary For CLLS

CLLS is in the medium-term down -15% below S&P in 2 months and down -34% below S&P in 5 months. In the long-term down -65% below S&P in 2 years and down -81% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities57.9 M Cash From Investing Activities-1.35 M Cash From Operating Activities41.73 M Gross Profit8.79 M
Net Profit6.14 M Operating Profit-3.56 M Total Assets339.77 M Total Current Assets331.52 M
Total Current Liabilities78.38 M Total Debt Total Liabilities77.89 M Total Revenue9.22 M
Technical Data
High 52 week29.86 Low 52 week13 Last close13.35 Last change-3.68%
RSI33.03 Average true range0.77 Beta1.51 Volume92.09 K
Simple moving average 20 days-9.2% Simple moving average 50 days-12.23% Simple moving average 200 days-27.22%
Performance Data
Performance Week-2.84% Performance Month-18.55% Performance Quart-29.74% Performance Half-21.65%
Performance Year-52.37% Performance Year-to-date-19.82% Volatility daily3.05% Volatility weekly6.82%
Volatility monthly13.97% Volatility yearly48.38% Relative Volume336.49% Average Volume118.51 K
New High New Low

News

2019-09-15 04:23:28 | Does Cellectis S.A. EPA:ALCLS Have A Particularly Volatile Share Price?

2019-08-06 16:30:00 | Cellectis Reports Financial Results for Second Quarter and First Six Months 2019

2019-07-08 16:30:00 | Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way

2019-06-26 16:30:00 | Cellectis S.A. Reports Results from Combined Shareholders Meeting Held on June 25, 2019

2019-05-07 16:32:00 | Cellectis Reports Financial Results for First Quarter 2019

2019-04-17 16:30:00 | Cellectis Announces Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual Meeting

2019-04-03 08:19:01 | The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

2019-04-02 16:30:00 | FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients

2019-03-11 16:10:00 | Cellectis Reports 4th Quarter and Full Year 2018 Financial Results

2019-03-07 16:30:00 | Cellectis Enters Lease Agreement to Build Manufacturing Facility, Advancing Towards Commercialization of its UCART Portfolio

2019-03-07 14:47:00 | 5 Top Gene-Editing Stocks for 2019

2019-02-25 17:10:00 | Cellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry

2019-02-07 07:25:00 | Consolidated Research: 2019 Summary Expectations for Oceaneering International, Southwest Gas, WellCare Health Plans, Barnes & Noble, Cellectis S.A, and Payment Data — Fundamental Analysis, Key Performance Indications

2018-12-10 16:30:00 | Cellectis Appoints William Monteith as Senior Vice President U.S. Manufacturing

2018-11-13 16:30:00 | Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2018

2018-10-17 08:10:00 | New Research Coverage Highlights Esperion Therapeutics, Summit Therapeutics, Ocwen Financial, Keane Group, Cellectis S.A, and Rapid7 — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-09-19 16:30:00 | CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board

2018-09-18 16:30:00 | Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP

2018-08-20 07:40:00 | Report: Exploring Fundamental Drivers Behind Ballard Power, Reading International, Odonate Therapeutics, Stitch Fix, Summit Therapeutics, and Cellectis S.A — New Horizons, Emerging Trends, and Upcoming Developments

2018-08-02 16:30:00 | Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer

2018-08-01 16:30:00 | Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018

2018-06-27 16:30:00 | Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2018

2018-06-12 16:30:00 | Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports

2018-06-08 09:56:22 | Should Cellectis SA.’s NASDAQ:CLLS Recent Earnings Decline Worry You?

2018-06-05 07:35:00 | Detailed Research: Economic Perspectives on Galapagos NV, Cellectis S.A, MediciNova, Logitech International S.A, The Descartes Systems Group, and Canadian Pacific Railway — What Drives Growth in Today's Competitive Landscape

2018-06-04 16:30:00 | FDA Grants Cellectis IND Approval for UCART22 in B-ALL

2018-05-22 19:59:00 | INSERTING and REPLACING: Approval of UCART123 Amendment in AML to Accelerate Clinical Development

2018-05-22 16:30:00 | Cellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical Development

2018-05-21 08:30:00 | Cellectis S.A.: Calyxt Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

2018-05-15 17:50:00 | Calyxt Announces Launch of Proposed Follow-On Offering

2018-05-10 17:15:00 | Cellectis to Present Data at the 2018 ASGCT Annual Meeting

2018-05-10 07:30:00 | Wired News - Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration with MSK to Develop Next-Generation CAR T Technologies

2018-05-07 16:30:00 | Cellectis Reports 1st Quarter 2018 Financial Results

2018-05-02 16:30:00 | Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia B-ALL

2018-05-01 07:01:00 | George Church, CRISPR Pioneer, Embraces Alternative Tech In Project To Recode A Human Genome

2018-05-01 07:00:00 | Harvard’s Wyss Institute Partners with Cellectis to Recode the Human Genome

2018-04-18 01:37:11 | Should Cellectis SA.’s EPA:ALCLS Recent Earnings Decline Worry You?

2018-04-13 08:15:29 | What Should We Expect From Cellectis SA.’s NASDAQ:CLLS Earnings Over The Next Few Years?

2018-04-11 07:40:00 | Consolidated Research: 2018 Summary Expectations for Ctrip.com International, JA Solar Holdings, Co., Oaktree Specialty Lending, Rhythm Pharmaceuticals, Cellectis S.A, and Travelport Worldwide — Fundamental Analysis, Key Performance Indications

2018-04-11 01:50:00 | Cellectis to Present Data at the 2018 AACR Annual Meeting

2018-04-10 16:10:00 | Cellectis Announces Closing of Follow-On Offering

2018-04-07 08:34:00 | Is Cellectis SA Stock a Buy Now?

2018-04-06 08:45:00 | Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again?

2018-04-05 16:34:00 | Why Micron Technology, Mechel, and Cellectis Slumped Today

2018-04-05 08:05:00 | Could Orgenesis ORGS be the Next Acquisition Target in Cell Therapy Space?

2018-04-04 20:30:00 | Cellectis Announces Pricing of Follow-On Offering

2018-04-03 17:45:00 | Cellectis Announces Launch of Follow-On Offering

2018-04-03 16:09:52 | Pfizer Takes On Gilead, Novartis With New Deal In Cancer Drugs

2018-04-03 13:14:41 | Pfizer in deal with Allogene to develop cancer cell therapies

2018-04-03 08:10:00 | Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies